Taysha Gene Therapies, Inc.
A clinical-stage biotech developing gene therapies for rare nervous-system diseases. Founded in 2019 out of the University of Texas Southwestern Medical Center in Dallas, its lead program TSHA-102 is designed to treat the genetic root cause of Rett syndrome by delivering a single MECP2 gene directly into the spinal fluid. The company takes its name from the Caddo word "taysha," meaning "friend" or "ally" — the same word that gave Texas its name.
Granted 21.3K
Granted 19.0K · Sold 200.0K
Granted 21.3K
Granted 21.3K
Granted 21.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Stalfort John A IIIDirector · 1 transaction | +1% | 2.06M | 21.3K | — | — |
| Nagendran SukumarPresident and Head of R&D, Director · 2 transactions | +1.4% | 1.34M | 19.0K | — | 200.0K |
| Donenberg Phillip B.Director · 1 transaction | +9.7% | 241.3K | 21.3K | — | — |
| Long Alison SDirector · 1 transaction | +20.2% | 127.2K | 21.3K | — | — |
| Sepp-Lorenzino LauraDirector · 1 transaction | +20.2% | 127.2K | 21.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -200.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.